Schedule Appointment
Schedule Appointment
What is Spravato? Spravato is an FDA-approved nasal spray used to treat treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal ideation. How does it work? By targeting the brain’s glutamate system, it offers rapid relief where traditional antidepressants may take weeks. Why choose Spravato? Its novel mechanism and fast-acting properties provide hope to patients who have not responded to other therapies. This comprehensive guide explains the treatment timeline, signs of effectiveness, available formulations, and what patients should expect during their Spravato treatment journey.
Spravato (esketamine) is a breakthrough treatment option designed to address the needs of patients with treatment-resistant depression (TRD) and those with major depressive disorder (MDD) accompanied by suicidal ideation. Unlike standard antidepressants that typically work on serotonin and norepinephrine pathways, Spravato targets the brain’s glutamate system. This approach not only facilitates rapid onset of action but also promotes reestablishment of neural connections and improved synaptic plasticity.
Approved by the U.S. Food and Drug Administration (FDA) in March 2019, Spravato represents a paradigm shift in depression treatment. It is a nasal spray formulation of esketamine – the S-enantiomer of ketamine – and is administered exclusively in certified healthcare settings under a Risk Evaluation and Mitigation Strategy (REMS) program. This system ensures that the treatment is dispensed safely, with comprehensive patient monitoring.
Next Step Psychiatry employs a compassionate, patient-centric approach to Spravato treatment, ensuring that each individual receives care that is tailored to their unique clinical needs. For more information about our treatment options, please visit our Spravato page or learn about the conditions we treat.
The journey with Spravato is structured into distinct phases, each designed to maximize effectiveness and ensure patient safety. Understanding these phases can empower patients by setting clear expectations regarding the treatment course.
During the induction phase, patients typically attend two treatment sessions per week. The goal is to quickly reduce depressive symptoms and stabilize the patient. A standard protocol involves:
This phase is critical, as early improvement in mood and energy levels is often observed within 24 to 48 hours after the first dose. However, while rapid relief is possible, some patients may require a longer period to notice significant changes. The induction phase typically lasts about 4 weeks, after which healthcare providers evaluate the patient's progress.
Once the induction phase yields noticeable improvements, the treatment transitions to the maintenance phase. In this phase, the frequency of treatment generally diminishes while continuing to prevent relapse and sustain progress:
| Frequency | Duration | Purpose |
|---|---|---|
| Weekly sessions | Weeks 5-8 | Consolidate improvements and adjust doses if needed. |
| Biweekly sessions | Ongoing | Maintain symptom remission and establish long-term stability. |
The maintenance phase is tailored to each patient’s clinical response and may vary in length. Some individuals continue with regular sessions for several months or even years, based on the severity of their depression and ongoing therapeutic response.
Recognizing the signs that Spravato is effective is essential, both for patient reassurance and for guiding treatment adjustments. Here are several indicators that suggest the treatment is producing positive results:
Some patients report a noticeable improvement in mood, energy, and overall outlook within just 24-48 hours. This rapid onset is one of Spravato’s hallmark features and stands in contrast to conventional antidepressants, which may require weeks to take effect.
Validated measurement scales, such as the Montgomery-Åsberg Depression Rating Scale (MADRS) and Patient Health Questionnaire-9 (PHQ-9), often indicate a significant decline in symptom severity over the first 4 weeks of treatment. A typical marker of success is a clinically meaningful reduction – often around 6 to 8 points – on these scales.
Patients frequently experience long-term benefits including improved emotional regulation, increased resilience to stress, and a more balanced mood. These changes can lead to a renewed interest in daily activities, social interactions, and self-care.
In addition to mood improvements, patients may notice enhanced concentration, clearer thinking, and increased motivation. Behavioral changes such as resuming hobbies, improved sleep quality, and better interpersonal relationships are also positive signs of treatment effectiveness.
It is important to consider progress over several weeks rather than relying on one single session. Regular assessments by a healthcare provider help determine whether adjustments in dosage or frequency are necessary to optimize outcomes.
Spravato is available in a nasal spray formulation that allows for effective, rapid absorption. The treatment uses a structured dosing regimen that is carefully adjusted based on individual patient needs. The following table compares the key formulations:
| Dosage | Frequency | Ideal Phase | Purpose |
|---|---|---|---|
| 56 mg | Twice weekly | Induction Phase | Establish initial response and adjust for tolerability. |
| 84 mg | Weekly to biweekly | Maintenance Phase | Maintain symptom remission and support long-term stability. |
Administration takes place under direct medical supervision due to potential side effects like dizziness, dissociation, and changes in blood pressure. Patients follow a strict protocol, which includes a brief waiting period between multiple devices if a higher dose is required. This ensures consistent absorption while allowing medical staff time to assess patient response after each dose.
In some cases, individualized adjustments are critical. For example, elderly patients or those with hepatic impairment may start at a lower dosage, with titration proceeding based on careful medical evaluation. Such individualized dosage strategies guarantee that each patient receives the most appropriate and safe treatment plan.
The success of Spravato treatment not only depends on the medication but also on thorough patient preparation, clear expectations, and ongoing support. Ensuring that patients understand the process can minimize anxiety and improve treatment adherence. Here is what patients should expect:
Patient safety is paramount during Spravato treatment. Adhering to the recommended guidelines, from pre-treatment preparations to post-session care, ensures a positive and controlled experience. Open communication with the treatment team is critical, so patients feel supported throughout their treatment journey.
Locating a certified Spravato treatment center is an essential step towards achieving relief from treatment-resistant depression. Next Step Psychiatry is committed to providing accessible, high-quality care through multiple locations across Georgia. Here are some tips and resources to help you find the right provider:
By ensuring you choose a provider that meets strict safety standards and offers comprehensive care, you can embark on your treatment journey with confidence. Next Step Psychiatry is dedicated to supporting you every step of the way—from your initial consultation to long-term maintenance therapy.
Many patients report initial improvements in mood, energy, and overall outlook within 24-48 hours. However, full therapeutic benefits are typically observed after approximately 4 weeks of regular treatment sessions.
Common side effects include dizziness, dissociation, nausea, and a temporary increase in blood pressure. These side effects are usually short-lived, and patients are closely monitored during and after each session.
Yes, most major insurance plans cover Spravato for treatment-resistant depression. It is important to verify your specific coverage details directly with your insurance provider or consult our Insurance Information page.
If you or a loved one is struggling with treatment-resistant depression, Spravato may offer a new pathway to recovery. At Next Step Psychiatry, our expert team is dedicated to providing personalized, compassionate care to help you regain control of your life.
Schedule your consultation today:
🖥️ Book Your Appointment Online
Learn more about our clinical services and our team dedicated to your mental health.